Nitric oxide is under clinical development by Novoteris and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Nitric oxide’s likelihood of approval (LoA) and phase transition for Mycobacterium Infections took place on 19 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nitric oxide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Nitric oxide overview
Nitric oxide (Thiolanox) is under development for the treatment of non-tuberculous mycobacteria pneumonia infections. The drug candidate is administered through inhalational route and topical route. It acts by targeting guanylate cyclase.
It was also under development for the treatment of tinea pedis (athlete's foot), cystic fibrosis, coronavirus disease 2019 (COVID-19) infection and associated lung complications.
Quick View Nitric oxide LOA Data
|Highest Development Stage|